The mRNA and protein expression of FABP5 was significantly higher in tumours from mice treated with bevacizumab than in mice treated with the control (Figure 8J-L).Moreover, we examined the expression of CA9 (a hypoxia marker) and FABP5 in tumour sections taken from xenograft mouse tumours by IHC. The gene discussed is FABP5; the disease is neoplasm.